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Purpose: The use of bisphosphonates for osteoporosis is effective in reducing the risk of
fractures. However, oral formulations are sometimes not well tolerated or are contraindi-
cated. Due to its availability in Brazilian public health system, pamidronate is frequently
prescribed for osteoporosis, despite the lack of studies demonstrating its anti-fracture efﬁ-
cacy and the absence of FDA or EMEA approval for this purpose. The aim of this study was
to  evaluate the bone mineral density (BMD) response to pamidronate in a group of women
with  osteoporosis in a tertiary care hospital.
Patients and methods: The medical records of women with osteoporosis who received
pamidronate for up to two years of treatment were reviewed. Patients were stratiﬁed at
high  or intermediate risk of fracture.
Results: A total of 70 women were in treatment with pamidronate. Among them, 74% were
at  high risk of fracture. A signiﬁcant gain in spine BMD after 24 months of treatment was
observed (p = 0.012). There was no difference between the groups of high and not high risk of
fracture. At the femur, no signiﬁcant increase in BMD was present, though, a strong negative
correlation with high PTH levels (r = −0.61; p = 0.003) was seen. In the multivariate analysis
BMI at 12 months had impact in the response to the treatment.
Conclusion: The intravenous pamidronate in a group of postmenopausal women with pre-
dominant high risk of fracture promoted an isolated gain in the spine BMD, even though,clinical randomized trials are needed to conﬁrm its anti-fracture efﬁcacy.
©  2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Please cite this article in press as: Zanatta LB, et al. Use of pamidronate for osteoporosis treatment in public health care in Brazil. Rev Bras
Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.005
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Uso  de  pamidronato  para  o  tratamento  da  osteoporose  no  sistema
público  de  saúde  no  Brasil
Palavras-chave:
Pamidronato
Densidade mineral óssea
Osteoporose
r  e  s  u  m  o
Justiﬁcativa: O uso de bisfosfonatos para a osteoporose é eﬁcaz na reduc¸ão do risco de
fraturas. No entanto, as formulac¸ões orais às vezes não são bem toleradas ou são con-
traindicadas. Em razão da sua disponibilidade no sistema público de saúde brasileiro, o
pamidronato é frequentemente prescrito para a osteoporose, apesar da falta de estudos
que  demonstrem a sua eﬁcácia antifratura e da ausência de aprovac¸ão da Food and Drug
Administration (FDA) ou da European Medicine Agency (Emea) para essa ﬁnalidade. O objetivo
deste  estudo foi avaliar a resposta da densidade mineral óssea (DMO) ao pamidronato em
um  grupo de mulheres com osteoporose em um hospital terciário.
Pacientes e métodos: Revisaram-se os prontuários médicos de mulheres com osteoporose que
receberam pamidronato por até dois anos de tratamento. As pacientes foram estratiﬁcadas
em  risco alto ou intermediário de fratura.
Resultados: Estavam em tratamento com pamidronato 70 mulheres. Entre elas, 74% tinham
alto  risco de fratura. Observou-se um ganho signiﬁcativo na DMO da coluna vertebral após
24  meses de tratamento (p = 0,012). Não houve diferenc¸a entre os grupos de risco de fratura
alto  e não alto. No fêmur, não foi encontrado aumento signiﬁcativo na massa óssea; contudo,
observou-se uma forte correlac¸ão negativa com altos níveis de PTH (r = -0,61; p = 0,003). Na
análise multivariada, o IMC aos 12 meses teve impacto na resposta ao tratamento.
Conclusão: O pamidronato intravenoso em um grupo de mulheres na pós-menopausa pre-
dominantemente com alto risco de fratura promoveu um ganho isolado na DMO da coluna
vertebral, embora sejam necessários ensaios clínicos randomizados para conﬁrmar sua
eﬁcácia antifratura.
© 2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Bisphosphonates represent the major drugs in the therapeu-
tic arsenal of osteoporosis. They are powerful anti-resorptive
agents, deposited in mineral bone, and their diversity in
action and anti-fracture efﬁcacy may be clinically warranted
depending on the strength of connection and detachment to
the bone tissue.1 Among the four bisphosphonates approved
for osteoporosis treatment, based on double-blind random-
ized controlled trials, zoledronate has the greatest afﬁnity for
bone, followed respectively by alendronate, ibandronate, and
risedronate.2
Pamidronate is a nitrogen-containing bisphosphonate with
an intermediary potency to inhibit bone reabsorption, and it
was initially indicated for preventing bone metastasis growth
in different types of cancer.1,3 The efﬁcacy of pamidronate has
been demonstrated in the treatment of lytic bone metastasis;
to control hypercalcemia of malignancy in multiple myeloma;
in the prevention of osteoporosis induced by glucocorticoids
or secondary to chemotherapy or immunosuppressive drugs
after solid organ and stem cell transplantation.4–13
The pamidronate has been extensibly used since 1991 and
became standardized by the public health agency for osteo-
porosis treatment. It started to be widely used due to its
availability in the public health care system and the lack of
other formally approved parenteral anti-resorptive drugs forPlease cite this article in press as: Zanatta LB, et al. Use of pamidronate
Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.005
osteoporosis treatment at that time. It is important to note
that this is the only non-oral medication for osteoporosis
treatment available in our public health care system. However,BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
pamidronate has never been approved for osteoporosis treat-
ment and, despite its frequent use in daily practice for many
patients with intolerance to oral bisphosphonates, prospec-
tive studies are lacking in evidence to support pamidronate’s
anti-fracture efﬁcacy.
Objectives
Primary
The aim of this study is to evaluate the therapeutic response
to pamidronate in the BMD gain of spine and total femur, in a
group of postmenopausal women with osteoporosis, followed
in an osteoporosis outpatient clinic for a treatment period of
up to 36 months.
Secondary
To evaluate the inﬂuence of clinical aspects such as age, frac-
ture risk, and dose of pamidronate administered per year on
the response to the treatment.
Methods
Study  design  and  patients for osteoporosis treatment in public health care in Brazil. Rev Bras
In 2006, due to the availability of intravenous pamidronate in
the Hospital de Clinicas da UFPR, the Bone Metabolism Unit
started its application in patients with osteoporosis.
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A retrospective study was conducted with patients on
reatment for osteoporosis with intravenous pamidronate.
he study was approved by the Ethics Committee on Human
esearch of the HC–UFPR.
atients
ll patients treated with pamidronate from October 2006 to
ctober 2010 were initially included. The vast majority of
atients had been diagnosed with postmenopausal osteoporo-
is, followed by glucocorticoid-induced osteoporosis. Patients
ith secondary osteoporosis due to malabsorptive syndromes,
astrointestinal surgery, prolonged immobilization, and intol-
rance to oral bisphosphonates were also included. The
xclusion criteria were males and patients with any dis-
ase that could interfere with bone or calcium or vitamin D
etabolism, as well as those with malignancies.
In Brazil, any algorithm is available to classify osteo-
orosis patients by the severity of risk factors for fracture.
atients were classiﬁed as having high and intermediate frac-
ure risk based on known clinical data, to date, the value of
MD  T score, own or family history of a past fragility frac-
ure, and risk factors for osteoporosis such as menopause
r premature ovarian failure, smoking, rheumatoid arthritis,
hronic use of glucocorticoids or immunosuppressive drugs,
ow weight, malabsorptive syndromes, prolonged immobiliza-
ion, and family history of osteoporosis.14
Considering that Frax algorithm is not recommended for
atients previously treated,15 we characterized patients tak-
ng into account traditional risk factors. High risk patients
ere: older than 75 years; own or family history of vertebral or
emoral fracture; older than 65 years with three or more  risk
actors for osteoporosis or with a T score <−3.0 SD.
In the intermediate risk group were those patients younger
han 75 years with two risk factors and no major osteoporotic
racture, or with a T score <−3.0 SD and less than two risk
actors; those younger than 65 years without risk factors with
ral intolerance to bisphosphonates, whereas the T score was
−3.0 SD or with osteopenia and one risk factor.
rotocol
s a retrospective study, the authors did not interfere with
he decision to use the medication and were not respon-
ible for the care of patients. Patients received intravenous
amidronate infusion, at a total dose of 90 mg  diluted in 500 ml
f saline or 5% dextrose solution, for a period of four hours,
very six months, according to the routine protocol of the Bone
etabolism Unit. All patients were vitamin D3 sufﬁcient at the
ime of the ﬁrst infusion and were supplemented with vita-
in  D and with calcium if their intake was below the daily
eeds.
MD  assessment
MD  at the lumbar spine (L1–L4) and total femur was mea-Please cite this article in press as: Zanatta LB, et al. Use of pamidronate 
Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.005
ured at 0, 12, 24, and 36 months of treatment by DXA, GE
unar Prodigy Advance PA +302284 (GE Medical Systems, Madi-
on, WI)  with a coefﬁcient of variability of 0.010 g/cm2 for
umbar spine and 0.012 g/cm2 for proximal femur and by 6;x  x x(x x):xxx–xxx 3
Hologic QDR – 1000W (Hologic, Inc., Waltham, MA), with a
coefﬁcient of variability of 0.046 g/cm2 for lumbar spine and
0.052 g/cm2 for proximal femur. The evaluation of each patient
was performed, considering only the results of the same
equipment.
Medical  records  evaluation
The medical records were reviewed in search of information
regarding gender; own or family history of a past fragility frac-
ture and risk factors for osteoporosis, such as menopause
or premature ovarian failure, smoking, rheumatoid arthri-
tis, chronic use of glucocorticoids or immunosuppressive
drugs, low weight, malabsorptive syndromes, or prolonged
immobilization. The results of creatinine (Picrato Alcaline
method, reference 0.57–1.11 mg/dL), parathyroid hormone –
PTH (Quimioluminescence method, reference 12–68 pg/ml)
and calcium (Arsenazzo III method, reference 8.5–10.5 mg/dL),
both using ARCHITECT ci8200®, Abbott; 25(OH) vitamin D3
(Quimioluminescence method – LIAISON®, DiaSorin, refer-
ence 30–100 ng/mL) of the ﬁrst time of infusion and of the
subsequent visits, when available, were captured.
Statistical  analysis
A descriptive analysis was performed and the results were
described as mean, median, minimum, maximum values, and
standard deviations. Student’s t test was used to evaluate
the gain in BMD between two particular moments for paired
samples. To compare the two different groups (high and inter-
mediate) between two particular time points, the Student’s t
test was performed for independent samples.
In order to quantify the association between two
variables–gain in BMD between two particular moments and
the determinant conditions of this variation, we  estimated the
Pearson correlation coefﬁcient, having investigated the follow-
ing variables: total pamidronate dose per year, age, BMI, and
PTH. The Fisher exact test assessed the association between
two dichotomous qualitative variables.
To predict the value of multiple variables to the response in
BMD  gain, an analysis of Multiple Linear Regression was done.
We applied the logistic regression model to assess the asso-
ciation between the explanatory variables and likelihood of
treatment response (characterized as gain or stability of BMD
at the time). The Wald test was used to evaluate the hypoth-
esis of interest on the explanatory variables. The results were
expressed as mean or median for parametric or nonpara-
metric data respectively and p value < 0.05 was considered
statistically signiﬁcant. Data were analyzed with the Statistica
v.8.0 software.
Results
Of the initial 127 patients, 39 were excluded, 14 men  and 25
female patients with the following diagnosis: primary hyper-for osteoporosis treatment in public health care in Brazil. Rev Bras
parathyroidism, hyperthyroidism, tumor-induced osteoma-
lacia, hypophosphatemic rickets, osteogenesis imperfecta,
ﬁbrous bone dysplasia, and malignancies. Four patients died
of other causes during treatment and two had pamidronate
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intolerance; the data of these six patients were not included
in the analysis. The total number of patients who showed no
exclusion criteria and who  completed the study was 74. Of this
total, 49 patients had BMD  evaluation in the ﬁrst year of treat-
ment, 21 in the second year, and only 18 in the third year of
treatment. The data of 70 patients who had BMD  in the ﬁrst
two years of treatment were analyzed.
During the treatment, a signiﬁcant loss of tracking of the
patients as well as a greater interval between the doses of
medication was observed. The mean dose decreased from
213 mg  per year in the ﬁrst 12 months to 167 mg  per year over
the next 24 months and to 150 mg  per year after 36 months of
follow-up.
Clinical,  laboratory,  and  demographic  data
A total of 70 women with a mean age of 68 years old, most
of whom (93%) were Caucasian and 49 (70%) at high risk of
fracture, were evaluated. The mean BMI  was 25.9 kg/m2, the
mean serum PTH was 50.78 (18–102) pg/mL, and the serum
calcium was 9.4 (8.4–10.4) mg/dL, within the normal range.
Among the group with high risk of fracture, 40 (80%) had
a fracture in the past, while in the intermediate risk group
only 6 (30%) had a past history of fracture. There were two
femoral fractures during the treatment, considered a treat-
ment failure, and pamidronate was substituted by teriparatide
at the 12- and 24-month time period, respectively. The clini-
cal characteristics are summarized in Table 1. Renal function,
assessed by Glomerular Filtration Rate (MDRD study equation)
between the periods of pamidronate application were normal.Please cite this article in press as: Zanatta LB, et al. Use of pamidronate
Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.005
Due to logistic reasons, renal function was not assessed rou-
tinely immediately after infusion of pamidronate, but before
the next infusion.
Table 1 – Demographic and clinical characteristics of
patients.
Total number 70
Age (years) Mean 68.9 (50–89)
BMI (kg/m2) Mean 25.9 (15–42)
Ethnicity
White 65 (92.85%)
Black 1 (1.40%)
Mulatto 4 (5.75%)
Risk
High 49 (70%)
Non-high 21 (30%)
Fracture
Vertebral 13 (18.57%)
Femur 12 (17.14%)
Non-vertebral 21 (30%)
PTH Mean 50.78 (18–102)
Calcium (mg/dL) Mean 9.42  (8.4–10.4)
GRF Mean 77.82 (35.1–168.8)
25OH D Mean 33.88 (12.8–76.8)
Calcium, (reference 8.5–10.5); PTH, Parathyroid hormone pg/mL (ref-
erence 12–68); GRF, Glomerular Filtration Rate mg/dL (MDRD study
equation); 25OHD, 25(OH) Vitamin D3 (reference 30–100 ng/mL);
BMI, body mass index. 1 6;x  x x(x x):xxx–xxx
Evaluation  of  the  effect  of  the  treatment  on  BMD  increment
The analysis of BMD  at the spine at 0, 12, and 24 months,
by Student’s t test, showed a signiﬁcant gain: an average of
0.024 g/cm2 (p = 0.012) after 24 months of treatment and a ten-
dency (p = 0.051) in the ﬁrst 12 months. No signiﬁcant change
in BMD at the femur was observed at the different time points
(Fig. 1).
The  inﬂuence  of  age,  PTH,  fracture  risk,  and  annual  dose
of pamidronate  on  the  BMD  change
In the spine, the linear association analysis did not show any
correlation between the BMD gain with age, PTH, past use of
bisphosphonates and the subgroups of fracture risk in any
time point of evaluation, however, the BMI  had a weak pos-
itive association with the BMD gain at 12 months (p = 0.046
and r = 0.29).
The BMD gain in femur showed a negative association with
PTH values at 24 months (p = 0.003 and r = −0.61) (Fig. 2) and
with BMI at 36 months (p = 0.002 and r = −0.78).
The multivariate analysis of the BMD gain in spine and
femur in each time point, as a dependent variable, and
age, PTH, fracture risk, and the annual dose of pamidronate
(considering the reduction of the dose per year according to
the time of treatment) as independent variables, revealed that
there was no evidence of association between the explana-
tory variables and the BMD gain in spine or femur in the
ﬁrst 12 months of treatment. Nevertheless, at 24 months, a
negative association was found between the gain in femoral
BMD  and the three variables: age, dose of pamidronate and
PTH (p = 0.002). When controlling either for PTH and dose of
pamidronate or for age and PTH, no signiﬁcance was found
(p = 0.220 and p = 0.788, respectively). However, controlling for
age and dose of pamidronate, a negative correlation was for osteoporosis treatment in public health care in Brazil. Rev Bras
observed between the PTH levels and femoral BMD  changes
(p = 0.005). Thus, it was estimated that for every increase of
1 pg/ml in PTH levels, there was a decrease of 0.0015 g/cm2 in
–0.01
12m
∗ P : .012
∗
 P=.051  
24m
–0.01
0.00
0.01
0.01
0.02
0.02
0.03
0.03
Spine Femur
Fig. 1 – Change in BMD  (mean g/cm2) at spine and total
femur in time.
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Fig. 2 – Correlation of the change in PTH levels and femur
BMD  after 24 months of treatment by Pearson correlation
coefﬁcient.
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Table 2 – Multivariable analysis of treatment response in
femur controlled for the main variables at 12 months.
Variable p Value Odds ratio 95% C.I.
Age 0.36 1.05 0.94–1.17
PTH 0.625 1.01 0.97–1.05
Risk estratiﬁcation 0.065 0.15 0.02–1.20
BMI (kg/m2) 0.043 1.25 1.00–1.55
Pamidronate dose
(mg/12 months)
0.279  1.01 0.99–1.02
Pamidronate dose was considered the reduction of the dose per year
according to the time of treatment.ge and dose of pamidronate).
he BMD  of femur; 33.1% of the femoral BMD  gain at 24 months
ere explained by age, PTH and dose of pamidronate (Fig. 3).
The multivariable analysis of the positive treatment
esponse (deﬁned as gain or stability of BMD  in time),
ontrolled for age, PTH, fracture risk, BMI  and dose of
amidronate, demonstrated an association of BMI with a pos-
tive response in femur (p = 0.043). It was estimated that for
ach increase in one unit of BMI  (kg/m2) the patient was 1.25
imes more  likely to respond to treatment – OR:1.25 (1.0–1.55)
Table 2). In the spine BMD,  controlling for the same variables,
nly a trend of association was observed between the positive
esponse to treatment and the highest administered dose of
amidronate per year (p = 0.052).
iscussionPlease cite this article in press as: Zanatta LB, et al. Use of pamidronate 
Reumatol. 2016. http://dx.doi.org/10.1016/j.rbre.2016.07.005
his retrospective study evaluating the BMD  response to intra-
enous pamidronate in a group of postmenopausal women
howed an increase in spine BMD  only after 24 months ofCI, conﬁdence interval; Treatment response, BMD gain/stability ver-
sus BMD loss; BMI, body mass index.
treatment, unlike other studies showing a positive response
after 12 months of treatment.16–19 In addition, there was no
change in femoral BMD, explained by the heterogeneity of
etiology of the osteoporosis in this group, short (24 months)
follow-up, and lower BMD speed gain at this site, which
could not be considered a treatment failure.20–22 But we  must
emphasize that when we  stratiﬁed the women according to
two subgroups of treatment response (responders and non-
responders), the main determinant for the femoral BMD  gain
was the BMI.
Despite the lack of studies demonstrating the efﬁcacy of
pamidronate in reducing the risk of vertebral or non-vertebral
fractures, this medication has been long used for the treat-
ment of diseases with increased bone turnover.5–13
Regardless the exclusion of patients with the diagnosis
of primary hyperparathyroidism, the previous treatment of
vitamin D deﬁciency before pamidronate infusion and the rec-
ommended supplementation of cholecalciferol and calcium
according to the local protocol, we still observed an elevated
PTH level in a subgroup of patients. Vitamin D deﬁciency
during the two years of treatment could not be excluded.
This reality reﬂects the majority of patients treated in our
institution, with low socioeconomic status, low capacity to
understand the treatment, and low attendance at medical
visits. Other possibilities are the low compliance of vitamin
D use, not available for free in a healthy public system, or the
use of pharmaceutical formulations without reliable quality.
As shown in this study, by statistical models of univari-
ate and multivariate analysis, PTH levels were correlated
with lower gain in femoral BMD, rich in cortical bone, an
observation already seen in either primary or secondary
hyperparathyroidism.23–26
The time of treatment expected for maximum anti-fracture
efﬁcacy and BMD gain is well established for alendronate,
but little is known about pamidronate.20–22 In this study we
observed a beneﬁt in spine BMD after 24 months. Unfortu-
nately, this study did not allow an analysis of the fracture risk
reduction.
We observed great difﬁculty in maintaining the proposed
therapeutic regimen, demonstrated by the tendency to reduce
the pamidronate dose per year, even though an alternativefor osteoporosis treatment in public health care in Brazil. Rev Bras
scheme of treatment was used (90 mg  pamidronate every
six months). This irregular use of pamidronate (in time and
dosage) can interfere with the observed results. This circum-
stances must be taken into account when treating the public
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health system patients. The demonstrated effectiveness of
the medications by studies under optimal conditions, does
not translate to the real life of our patients. The long-term
difﬁculty in maintaining treatment, as well as the required
treatment adherence, could impair the results of this thera-
peutic regimen.
Numerous limitations were observed, since this was a real
life, cross-sectional study and not a double-blind randomized
controlled trial. The group that received pamidronate was not
homogeneous, had a high risk of fracture, lost infusions, and
possibly had a concomitant vitamin D deﬁciency. However,
the importance of this study was not lost, because it reﬂects
the reality seen in patients with poor socioeconomic status
and low attendance at medical visits. Rather, it exposes a crit-
ical view that under these treatment conditions (either the
patient or the infrastructure available) we will not get a favor-
able result as presented in other studies.16–19 Moreover, as the
pamidronate is not yet an approved medication for osteoporo-
sis treatment and has great adherence concerns, our health
care system should review its standardization for this purpose.
Conclusion
Our study demonstrated that the use of intravenous
pamidronate increased spine BMD  after 24 months of treat-
ment. No response was observed in femoral BMD. This
population reﬂects the majority of patients treated in our
service, and maybe in other tertiary care hospitals in our
country. Pamidronate is not an approved medication for osteo-
porosis treatment; however, it is the only non-oral option
available in our public health system for patients who have
osteoporosis and contraindications to oral bisphosphonates.
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The authors declare no conﬂicts of interest.
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